Loading clinical trials...
Loading clinical trials...
A Multicenter, Double-Blind, Randomized Trial of the Relationship of Intragastric Acid Control and Healing Status of Moderate and Severe Erosive Esophagitis After Treatment With Esomeprazole Magnesium (NEXIUM®) 10 mg and 40 mg Once Daily
The purpose of this study is to decide if controlling stomach acid is related to healing of erosive esophagitis after treatment with esomeprazole magnesium (NEXIUM®) 10 mg and 40 mg once daily.
Age
18 - 75 years
Sex
ALL
Healthy Volunteers
No
Research Site
Alabaster, Alabama, United States
Research Site
Anaheim, California, United States
Research Site
Dinuba, California, United States
Research Site
Fresno, California, United States
Research Site
Orange, California, United States
Research Site
San Diego, California, United States
Research Site
Bridgeport, Connecticut, United States
Research Site
Fort Lauderdale, Florida, United States
Research Site
Hialeah, Florida, United States
Research Site
Jacksonville, Florida, United States
Start Date
June 1, 2004
Completion Date
August 1, 2005
Last Updated
March 26, 2009
120
Estimated participants
esomeprazole magnesium (oral medication)
DRUG
Lead Sponsor
AstraZeneca
NCT07010107
NCT06850480
NCT00574327
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions